UNLABELLED: Hepcidin is a regulator of iron balance that is increased in obesity. It reduces the absorption of iron, reduces the transfer of iron from macrophages to the plasma and/or prevents mobilisation of stored iron. Obese patients with non-alcoholic fatty liver disease (NAFLD) demonstrate adipokine and cytokine release promoting inflammatory response. We aimed to analyse the hepcidin levels and iron metabolism in obese children with and without NAFLD and non-obese healthy controls. The study population consisted of 110 children aged 7-18 years in three groups: 50 obese patients without NAFLD, 30 obese patients with NAFLD, and 30 non-obese healthy controls. Serum hepcidin, ferritin, and iron levels, iron-binding capacity, lipid profile, and liver function tests were measured, and hepatic ultrasonography was performed in all participants. Obese patients' white blood cell counts, total cholesterol, triglyceride levels, and homeostatic model assessment of insulin resistance (HOMA-IR) were significantly higher than those of the control group. Iron-binding capacity was significantly higher in obese patients without NAFLD compared with obese patients with NAFLD (p = 0.002). Hepcidin levels were not significantly different between obese patients and the control group. However, hepcidin levels in obese patients with NAFLD were significantly higher than those in obese patients without NAFLD (p < 0.001). CONCLUSIONS: Hepcidin levels were significantly higher in obese children with NAFLD than those without NAFLD. Obese children with NAFLD should receive attention regarding iron metabolism disorders. Serum hepcidin could be a marker of iron metabolism status and NAFLD in these groups of patients.
UNLABELLED: Hepcidin is a regulator of iron balance that is increased in obesity. It reduces the absorption of iron, reduces the transfer of iron from macrophages to the plasma and/or prevents mobilisation of stored iron. Obesepatients with non-alcoholic fatty liver disease (NAFLD) demonstrate adipokine and cytokine release promoting inflammatory response. We aimed to analyse the hepcidin levels and iron metabolism in obesechildren with and without NAFLD and non-obese healthy controls. The study population consisted of 110 children aged 7-18 years in three groups: 50 obesepatients without NAFLD, 30 obesepatients with NAFLD, and 30 non-obese healthy controls. Serum hepcidin, ferritin, and iron levels, iron-binding capacity, lipid profile, and liver function tests were measured, and hepatic ultrasonography was performed in all participants. Obesepatients' white blood cell counts, total cholesterol, triglyceride levels, and homeostatic model assessment of insulin resistance (HOMA-IR) were significantly higher than those of the control group. Iron-binding capacity was significantly higher in obesepatients without NAFLD compared with obesepatients with NAFLD (p = 0.002). Hepcidin levels were not significantly different between obesepatients and the control group. However, hepcidin levels in obesepatients with NAFLD were significantly higher than those in obesepatients without NAFLD (p < 0.001). CONCLUSIONS:Hepcidin levels were significantly higher in obesechildren with NAFLD than those without NAFLD. Obesechildren with NAFLD should receive attention regarding ironmetabolism disorders. Serum hepcidin could be a marker of iron metabolism status and NAFLD in these groups of patients.
Authors: Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz Journal: Blood Date: 2002-11-14 Impact factor: 22.113
Authors: L B Yanoff; C M Menzie; B Denkinger; N G Sebring; T McHugh; A T Remaley; J A Yanovski Journal: Int J Obes (Lond) Date: 2007-04-17 Impact factor: 5.095
Authors: Marloes P van der Aa; Soulmaz Fazeli Farsani; Lisa A J Kromwijk; Anthonius de Boer; Catherijne A J Knibbe; Marja M J van der Vorst Journal: Clin Pediatr (Phila) Date: 2013-11-14 Impact factor: 1.168
Authors: Sang Hyub Lee; Sook-Hyang Jeong; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Nayoung Kim; Dong Ho Lee Journal: Korean J Hepatol Date: 2010-09
Authors: Christian Visscher; Lea Middendorf; Ronald Günther; Alexandra Engels; Christof Leibfacher; Henrik Möhle; Kristian Düngelhoef; Stefan Weier; Wolfram Haider; Dimitri Radko Journal: Lipids Health Dis Date: 2017-05-30 Impact factor: 3.876
Authors: Teresa Auguet; Gemma Aragonès; Alba Berlanga; Salomé Martínez; Fàtima Sabench; Jessica Binetti; Carmen Aguilar; José Antonio Porras; Alicia Molina; Daniel Del Castillo; Cristóbal Richart Journal: PLoS One Date: 2017-10-24 Impact factor: 3.240
Authors: Sandro Altamura; Stefan Kopf; Julia Schmidt; Katja Müdder; Ana Rita da Silva; Peter Nawroth; Martina U Muckenthaler Journal: J Mol Med (Berl) Date: 2017-10-03 Impact factor: 4.599